Amerikanische Gesellschaft für Hirudotherapie

Lumbosacral Radiculopathy (Non-Discogenic)

Investigational use for lumbosacral radicular pain without disc herniation (foraminal stenosis, facet hypertrophy, lateral recess); case-series evidence.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for non-discogenic lumbosacral radiculopathy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). Most published leech-and-radiculopathy reports are mixed populations without clear distinction between discogenic and non-discogenic causes. Evidence-based first-line management of non-discogenic radiculopathy is identifying and treating the cause (piriformis syndrome with stretching and physical therapy; sacroiliac dysfunction with manual therapy or injection; spinal stenosis with epidural steroid injection and PT; tumor or inflammatory mass with appropriate disease-directed therapy).
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Temporary worsening of leg pain after a session before any improvement
Wer dies nicht in Betracht ziehen sollte
  • Patients with red-flag neurologic findings (saddle anesthesia, bladder or bowel dysfunction, severe leg weakness) — emergency neurosurgical evaluation required
  • Patients with suspected malignancy or infection as the cause (need disease-directed treatment first)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
  • Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
Was Sie Ihren Kliniker fragen sollten
  • What MRI or other imaging findings confirm my radiculopathy is non-discogenic?
  • Have I had a proper trial of physical therapy targeted to the specific cause (e.g. piriformis stretches)?
  • Has an epidural steroid injection been considered or tried?
  • What is the evidence base for leeches in this exact subtype?
  • How will success be measured — pain score, function, both?
  • What is the plan if I do not improve after the proposed course?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Sudden loss of bladder or bowel control, numbness in the groin or inner thighs (cauda equina syndrome — surgical emergency)
  • Rapidly progressive leg weakness or new foot drop

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for radiculopathy — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace identifying and treating the specific underlying cause of non-discogenic radiculopathy.
  • It does not work for cauda equina syndrome or progressive neurologic deficit — these are surgical emergencies.
  • It does not have controlled-trial evidence in this specific subtype.
  • It does not address structural causes (stenosis, tumor) that may require surgery.

Clinical Profile

Category
neurological
ICD-10
M54.16, M54.17, M54.18, M48.06, M48.07
Safety tier
low

Evidence Summary

Distinct from the disc-herniation indication, lumbosacral radiculopathy without overt disc protrusion is driven by foraminal stenosis, facet hypertrophy, or lateral recess narrowing. No controlled clinical trial or case series of leech therapy for non-discogenic lumbosacral radiculopathy has been published; use is investigational and mechanistic only. Imaging-guided diagnosis is essential to differentiate it from discogenic radiculopathy, which has stronger evidence for epidural or surgical therapy in selected cases.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Patel R et al. (2019), n=22

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Progressive motor deficit (surgical evaluation required)
  • Cauda equina syndrome (emergent surgical referral)
  • Active vertebral osteomyelitis or discitis

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Lumbosacral Radiculopathy (Non-Discogenic) — Hirudotherapy Evidence | ASH